Skip to main content
. Author manuscript; available in PMC: 2020 Mar 15.
Published in final edited form as: Cancer Res. 2019 Jan 14;79(6):1047–1053. doi: 10.1158/0008-5472.CAN-18-3126

Figure 2.

Figure 2.

Workflow for molecular testing in colorectal carcinoma. Testing for MSI/ MMR status should be performed universally in CRC. Patients with metastatic MSS/ MMR-P CRC should undergo next generation sequencing or RAS/ BRAF mutation testing. Patients with MLH1 deficiency of MSI-H results without available MMR IHC should undergo MLH1 promoter hypermethylation testing. If MLH1 promoter hypermethylation is detected in metastatic CRC and the tumor is negative for BRAF p. V600E, fusion testing should be performed. Patients with MMR-D of MSH2, MSH6, or PMS2 should receive germline testing.